SynthesisFrontiers in pharmacology2026
Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ivonescimab (AK112), a novel bispecific antibody targeting PD-1 and VEGF, has emerged as a promising therapeutic agent in the treatment of non-small cell lung cancer (NSCLC). This study aims to comprehensively evaluate its efficacy and safety. Materials and methods: A comprehensive literature search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library (from inception to January 2026) to identify studies reporting the clinical efficacy and safety outcomes of AK112 in NSCLC. Pooled analyses were conducted for efficacy endpoints, including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS), as well as adverse events (AEs). For randomized controlled trials (RCTs), odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were calculated for binary and time-to-event outcomes, respectively. Subgroup analyses were performed by cancer type and treatment regimen. Results: 5 studies comprising 1,365 patients were included. AK112-based regimens significantly improved ORR (OR = 1.65, 95% CI: 1.31-2.09) and DCR (OR = 2.29, 95% CI: 1.18-4.44) compared to control treatments. A significant progression in PFS was observed (HR = 0.53, 95% CI: 0.45-0.62). The PFS benefit was consistent across all PD-L1 expression subgroups. Safety analysis revealed that AK112-based regimens increased the risk of all-grade AEs (OR = 2.05, 95% CI: 1.20-3.51) and grade ≥3 AEs (OR = 1.51, 95% CI: 1.19-1.92). Conclusion: AK112 demonstrates significant efficacy and a manageable safety profile in advanced NSCLC, supporting its role as a valuable treatment option. Further studies are needed to confirm long-term survival benefits. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251176434.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.